MarketPeel
Insider Trading Intelligence
Pricing
…
GB

Gunther Birznieks

VNDA
SVP, BUSINESS DEVELOPMENT · VANDA PHARMACEUTICALS INC. · CIK 0001702031
FILING MIX · LIFETIME46%/54%
BUYS
12
SELLS
14
TOTAL VALUE
$1.46M
COMPANIES
1
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
494,197
AVG SELL PX
$9.00
TRADE KIND
SHOWING 26 / 26
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
12 backtested trades · 8 horizons · 3 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Gunther Birznieks, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d12+66.67%-2.12%-2.31%+0.18%+0.44%—
14d12+66.67%-6.05%-3.10%-2.94%-4.77%—
30d12+58.33%-1.94%-1.44%-0.49%+3.37%—
60d12+50.00%-3.88%+0.16%-4.04%-3.08%—
90d12+66.67%-4.04%+0.36%-2.86%-9.71%—
180d12(1 pending)+81.82%-4.46%+8.90%-13.35%-23.61%—
1y12(1 pending)+63.64%-7.15%+16.04%-23.20%-36.02%—
2y12(1 pending)+72.73%-11.01%+34.04%-45.05%-69.93%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
VNDA · 494,197 shares · as of Mar 2, 2026
0134,157268,314402,471536,628202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 12 buys / 14 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
42,431$8.27$350.7K494,197Mar 2, 2026Mar 4, 2026 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
125,000——536,628Feb 18, 2026Feb 19, 2026 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
26,941$4.76$128.2K411,628Mar 1, 2025Mar 4, 2025 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
125,000——438,569Feb 18, 2025Feb 20, 2025 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
8,684$4.13$35.9K313,569Mar 5, 2024Mar 6, 2024 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
8,727$4.30$37.5K322,253Mar 4, 2024Mar 6, 2024 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
125,000——330,980Feb 16, 2024Feb 21, 2024 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
8,268$6.26$51.8K205,980Mar 3, 2023Mar 6, 2023 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
8,509$6.20$52.8K214,248Mar 2, 2023Mar 6, 2023 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
32,700——222,757Feb 16, 2023Feb 21, 2023 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
77,500——77,500Feb 16, 2023Feb 21, 2023 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASE
SVP, Business Development
1,250$3.12$3.9K190,057Aug 26, 2022Aug 29, 2022 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
1,250——0Aug 26, 2022Aug 29, 2022 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
11,517$11.27$129.8K188,807Mar 2, 2022Mar 2, 2022 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
4,084$11.19$45.7K200,324Mar 1, 2022Mar 2, 2022 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
77,500——77,500Feb 28, 2022Mar 2, 2022 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
32,700——204,408Feb 28, 2022Mar 2, 2022 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
16,620$18.19$302.3K171,708Mar 2, 2021Mar 3, 2021 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
3,845$18.66$71.7K188,328Mar 1, 2021Mar 3, 2021 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
32,700——192,173Feb 24, 2021Feb 26, 2021 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
77,500——77,500Feb 24, 2021Feb 26, 2021 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
5,535$10.66$59.0K159,473Mar 3, 2020Mar 3, 2020 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
12,223$10.04$122.7K165,008Mar 2, 2020Mar 3, 2020 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
30,000——177,231Feb 26, 2020Feb 28, 2020 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
70,000——70,000Feb 26, 2020Feb 28, 2020 ↗View →
VNDA
VANDA PHARMACEUTICALS INC.
SALE
SVP, Business Development
4,020$15.93$64.0K147,231Jan 2, 2020Jan 6, 2020 ↗View →
Other insiders · VNDA
Loading peer insiders…
About this filer
CIK 0001702031
ROLE
SVP, Business Development
PRIMARY
VNDA
COMPANIES
1
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001702031DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback